Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) – Equities research analysts at Zacks Research boosted their Q1 2026 earnings per share estimates for shares of Corcept Therapeutics in a research note issued on Monday, January 27th. Zacks Research analyst K. Das now anticipates that the biotechnology company will earn $0.46 per share for the quarter, up from their previous forecast of $0.45. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.35 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q2 2026 earnings at $0.56 EPS, Q3 2026 earnings at $0.74 EPS, Q4 2026 earnings at $0.74 EPS and FY2026 earnings at $2.50 EPS.
Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last released its earnings results on Wednesday, October 30th. The biotechnology company reported $0.41 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.14. The firm had revenue of $182.55 million for the quarter, compared to analysts’ expectations of $171.97 million. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The company’s quarterly revenue was up 47.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.28 earnings per share.
View Our Latest Stock Analysis on Corcept Therapeutics
Corcept Therapeutics Stock Performance
Shares of Corcept Therapeutics stock opened at $69.90 on Wednesday. Corcept Therapeutics has a 1 year low of $20.84 and a 1 year high of $70.60. The firm’s 50-day moving average is $55.83 and its 200 day moving average is $46.67. The stock has a market cap of $7.32 billion, a price-to-earnings ratio of 55.48 and a beta of 0.56. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.70 and a quick ratio of 3.64.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in CORT. Capital Performance Advisors LLP bought a new position in shares of Corcept Therapeutics during the 3rd quarter valued at approximately $25,000. Kathleen S. Wright Associates Inc. bought a new stake in Corcept Therapeutics during the 3rd quarter worth approximately $36,000. USA Financial Formulas purchased a new position in Corcept Therapeutics during the fourth quarter valued at approximately $54,000. Newbridge Financial Services Group Inc. bought a new position in shares of Corcept Therapeutics in the fourth quarter worth approximately $58,000. Finally, Principal Securities Inc. increased its stake in shares of Corcept Therapeutics by 63.6% in the fourth quarter. Principal Securities Inc. now owns 1,243 shares of the biotechnology company’s stock worth $63,000 after purchasing an additional 483 shares in the last quarter. Institutional investors own 93.61% of the company’s stock.
Insider Activity
In other Corcept Therapeutics news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $50.54, for a total value of $111,188.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Joseph Douglas Lyon sold 1,411 shares of the business’s stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $56.72, for a total transaction of $80,031.92. Following the sale, the insider now directly owns 8,494 shares of the company’s stock, valued at approximately $481,779.68. The trade was a 14.25 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 31,405 shares of company stock valued at $1,627,772 in the last ninety days. 20.50% of the stock is currently owned by company insiders.
About Corcept Therapeutics
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
Read More
- Five stocks we like better than Corcept Therapeutics
- Earnings Per Share Calculator: How to Calculate EPS
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- Financial Services Stocks Investing
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.